Overactive bladder medications help many California patients — but they also have one of the highest discontinuation rates of any chronic medication class. Understanding why can help San Diego women make more informed treatment decisions and know when to ask about alternatives.
The Antimuscarinic Class: Common Side Effects
Antimuscarinic OAB medications — oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, trospium — block muscarinic receptors throughout the body, not just in the bladder. This produces predictable side effects in other organ systems.
Dry mouth is the most disruptive side effect for many San Diego OAB patients. At therapeutic doses, rates range from 20–65% depending on the specific medication and dose. Severe dry mouth affects eating, speaking, taste, dental health, and sleep quality. It is the leading reason patients stop antimuscarinic OAB medications in California.
Constipation affects a significant portion of patients and can be particularly problematic for California women who already have bowel irregularity. Constipation worsens bladder pressure and may paradoxically worsen OAB symptoms.
Blurred vision is less common but occurs with some antimuscarinics and can be a safety concern, especially for older San Diego patients who drive.
Urinary retention — antimuscarinics can reduce the ability to empty the bladder completely. This is particularly relevant for patients who already have slow or incomplete emptying.
The Dementia and Memory Question
A SUFU (Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction) white paper reviewed the published evidence and concluded that the literature supports a likely small but significant increased dementia risk with chronic exposure to OAB anticholinergic medications. The risk is most relevant for older California patients, those with existing cognitive vulnerability, and those using higher-dose or longer-term anticholinergics.
This concern has driven a significant shift in San Diego clinical practice toward beta-3 agonists (mirabegron, vibegron) as preferred first-line pharmacotherapy in older patients, and toward earlier consideration of neuromodulation in those with persistent symptoms.
What to Do If Medications Aren't Working
Documented intolerance or inadequate response to OAB medications is clinically meaningful. California insurance plans — including Medicare (NCD 230.18), Aetna (CPB 0223), Blue Cross (CG-SURG-95), Cigna (mm_0404), and UnitedHealthcare — use prior medication history as part of the criteria for covering advanced therapies like sacral neuromodulation.
California Bladder's San Diego team specializes in helping patients transition from failed medications to advanced therapy. Call (858) 571-3630.
This article is for informational purposes only and does not constitute medical advice. Coverage information is general; individual plan requirements vary. A clinical evaluation is required.